Roche Pharmaceuticals Names New CEO as O'Day Leaves to Head Gilead -- Update
December 10 2018 - 3:10AM
Dow Jones News
(Adds detail about departing CEO, Gilead confirmation)
By Cristina Roca
Roche Holding AG (ROG.EB) on Monday said it has appointed a new
chief executive for its Roche Pharmaceuticals business to replace
the current CEO, who is leaving the company to head Gilead Sciences
Inc. (GILD).
The Swiss pharmaceuticals company said Monday that CEO Daniel
O'Day will step down as of Dec. 31, and that it is appointing
William Anderson to the post effective Jan. 1.
Separately on Monday, Gilead said in a press release that it has
appointed Mr. O'Day as chief executive and chairman of its board
effective March 1. The U.S. biopharmaceutical company named Gregg
Alton interim CEO for the period between Jan. 1 and Mr. O'Day's
start date.
Roche said Mr. Anderson will also join its corporate executive
committee.
Mr. Anderson is currently chief executive of Genentech, a Roche
subsidiary company. He has worked for Roche since 2006.
Separately, Roche said it was proposing Hans Clevers for
election to its board of directors. Mr. Clevers is a professor of
molecular genetics at University Medical Center Utrecht, the
company said.
Write to Cristina Roca at cristina.roca@dowjones.com;
@_cristinaroca
(END) Dow Jones Newswires
December 10, 2018 02:55 ET (07:55 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024